Analyst Price Target is $6.25
▲ +57.83% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Nuvation Bio in the last 3 months. The average price target is $6.25, with a high forecast of $10.00 and a low forecast of $5.00. The average price target represents a 57.83% upside from the last price of $3.96.
Current Consensus is
Buy
The current consensus among 4 contributing investment analysts is to buy stock in Nuvation Bio. This Buy consensus rating has held steady for over two years.
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.
Read More